Patients

If you are interested in learning more about participating in the ABS-1230 Phase 1b/2 clinical trial, please visit ActioTrials.com, where you can find details about current studies, eligibility, and trial locations.
KCNT1 Epilepsy Foundation
For more information about KCNT1-related epilepsy, new therapies in development, the latest research information and resources for families and caregivers, please visit the KCNT1 Epilepsy Foundation website. The Foundation provides educational materials and a supportive community for families navigating this rare disease.
Expanded Access Policy
Our purpose at Actio Biosciences, Inc. is to develop new therapies that have a positive impact on patient health, and to serve patients, patient families and patient communities through education, empathy, and awareness. Read more…
